FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
246 letters match. Newest first.
-
DrugsDermacare dba Filler Outlet
South Korea's Dermacare, doing business as Filler Outlet, sells unapproved, misbranded injectable botulinum toxin to U.S. consumers through its website.
High risk -
DrugsEstaderma
FDA warned South Korea's Estaderma that its website sells unapproved, misbranded injectable botulinum toxin (Liztox) to U.S. consumers.
High risk -
DrugsKorean Aesthetic dba Korean Fillers
FDA warned Korean Fillers that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
High risk -
DrugsAceCosm
AceCosm’s website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers, FDA says.
High risk -
DrugsDermax Co., Ltd
FDA warned China's Dermax Co., Ltd. over its website selling unapproved, misbranded injectable botulinum toxin to U.S. consumers.
High risk -
DrugsGlow Nest Beauty
FDA warned Glow Nest Beauty that its website sells unapproved, misbranded injectable botulinum toxin Rentox 200U.
High risk -
DrugsElle Pharm
FDA warned Elle Pharm that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
High risk -
DrugsCOSMO KOREA
FDA told South Korea's COSMO KOREA that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
High risk -
DrugsGlam Derma
FDA warns Glam Derma over website selling unapproved, misbranded injectable botulinum toxin products.
High risk -
DrugsMJS Medicals
FDA warned South Korea's MJS Medicals for selling unapproved, misbranded botulinum toxin ("Innotox") to U.S. consumers online.
High risk -
DrugsDerma Solution
FDA warned Derma Solution for selling unapproved, misbranded injectable Botulax botulinum toxin drugs online to U.S. consumers.
High risk -
DrugsGlowface
Glowface's website sells unapproved, misbranded injectable Botulax botulinum toxin drugs to U.S. consumers, FDA says.
High risk -
Drugsonlineotcmeds.com
FDA warned onlineotcmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and Schedule II stimulants to U.S. consumers online.
High risk -
Drugswww.usmedschoice.com
FDA warned www.usmedschoice.com for selling unapproved and misbranded opioids, benzodiazepines, and stimulants online without prescriptions.
High risk -
DrugsDixon Investments Inc. dba ARI
FDA cites Dixon Investments (ARI) for manufacturing-rule and unapproved/misbranded OTC aerosol drug violations.
High risk -
Drugsmotionpharmacy.com
FDA warns motionpharmacy.com over selling unapproved and misbranded prescription drugs online.
High risk -
Drugscheaptrustedpharmacy.com
cheaptrustedpharmacy.com sells unapproved, misbranded prescription drugs to U.S. consumers online, FDA warns.
High risk -
DrugsFWD Care, Inc. dba FWD
FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.
Medium -
DrugsDermacare LLC dba BlueChew
FDA warned BlueChew over website claims that its compounded sildenafil and tadalafil are the same as Viagra and Cialis.
High risk -
DrugsHims & Hers Health, Inc. dba Hers
FDA warned Hims & Hers (Hers) that its website misleads consumers about compounded semaglutide by implying it is the same as approved Ozempic and Wegovy.
Medium -
DrugsAytu Biopharma
FDA says Aytu Biopharma’s sponsored links for ADHD drug Cotempla XR-ODT are false or misleading and misbrand it.
High risk -
DrugsAytu Biopharma
FDA warned Aytu Biopharma that sponsored links for ADHD drug Adzenys XR-ODT are false or misleading because they omit risk information.
High risk -
DrugsSlendid
FDA warned Slendid that its website sells compounded semaglutide and tirzepatide with a false "clinically proven" claim, making the drugs misbranded.
Medium -
DrugsHello Cake, Inc. dba Hello Cake
FDA warns Hello Cake, an online telehealth seller, that its website misbrands compounded sildenafil and tadalafil ED drugs as equivalent to Viagra and Cialis.
Medium -
DrugsTRYM Health, Inc. dba TRYM Health
FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.
Medium -
DrugsMatthew Stern, CEO MyStart Health LLC.
FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.
Low -
DrugsAlora Pharmaceuticals
FDA says Alora's paid search ads for RELEXXII ADHD drug are false or misleading because they omit risk information.
Low -
DrugsCurex
FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.
High risk -
DrugsNovo Nordisk Inc.
FDA says Novo Nordisk’s Oprah Winfrey video makes Wegovy, Ozempic and Victoza look safer than their labels allow.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly's Zepbound online video omitted risk and limitations information and was not submitted to FDA.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.
Low -
Drugswww.usaquickmeds.com
FDA warned usaquickmeds.com for selling unapproved and misbranded opioids and benzodiazepines online without prescriptions.
High risk -
DrugsK & Care Organics
FDA warns K & Care Organics over unapproved over-the-counter (OTC) foam sunscreen drugs sold in the U.S. without required authorization.
High risk -
DrugsSupergoop!
FDA warned Supergoop! that its over-the-counter sunscreen body mousse is illegally labeled because foam dosage forms are not allowed under the sunscreen monograph.
Medium -
DrugsConfer With
FDA told London-based Confer With that its Vivant True Tone skin-lightening serum is an unapproved drug sold without FDA approval.
High risk -
Drugswww.mysteroidsmarket.com
FDA warns Israel-based website mysteroidsmarket.com for selling unapproved and misbranded stimulants and benzodiazepines to U.S. consumers.
High risk -
Drugswww.d-pharmacy.com
FDA warned Singapore website d-pharmacy.com for selling unapproved prescription opioids, benzodiazepines, and stimulants to U.S. consumers.
High risk -
Drugswww.portmeds.com
FDA warned www.portmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and Schedule II stimulants online without prescriptions.
High risk -
Drugswww.plakini-pharma.com
FDA warned Malaysia-based website plakini-pharma.com for selling unapproved, misbranded opioids, benzodiazepines, and stimulants to U.S. consumers.
High risk -
DrugsCovalent Medical
FDA warned Covalent Medical that its FOCUS PI post-injection eye drops are an unapproved new drug with claims not allowed for over-the-counter eye products.
Medium -
DrugsRevitalize Energy, Inc.
FDA warned Revitalize Energy that its Revitalize Energizing Eye Drops are an unapproved new drug and misbranded.
High risk -
DrugsThea Pharma, Inc.
FDA warns Thea Pharma that IVIZIA OTC lubricant eye drops are an unapproved and misbranded new drug.
High risk -
DrugsEyeTech One, LLC
FDA warns EyeTech One that its EYELIVIO lubricant eye ointment is an unapproved new drug and misbranded.
Medium -
Drugswww.buynetmeds.com
FDA warned www.buynetmeds.com for selling unapproved, misbranded tapentadol and semaglutide drugs, including injectables, to U.S. consumers online.
High risk -
Drugswww.soma4ever.com
FDA warned soma4ever.com for selling unapproved and misbranded opioids, benzodiazepines, and stimulants to U.S. consumers online.
High risk -
DrugsSterling Distributors
FDA warned Florida drug wholesaler Sterling Distributors for shipping prescription drugs without licenses and ignoring a counterfeit report.
High risk -
Drugswww.peacefulmeds.com
FDA warned www.peacefulmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and injectable semaglutide to U.S. consumers online.
High risk -
Drugswww.buyprosoma.com
FDA warned www.buyprosoma.com for selling unapproved, misbranded opioids and benzodiazepines to U.S. consumers online.
High risk -
DrugsZhejiang Huahai Pharmaceutical Co., Ltd.
FDA warns Zhejiang Huahai Pharmaceutical over CGMP violations including dirty equipment, aseptic-area tape, and data integrity issues.
High risk